Articles tagged with Metastasis
Researchers have found that Plexin-B1 represents a new candidate therapeutic target to treat patients with breast cancer found to overexpress the molecule ErbB-2. Overexpression of ErbB-2 led to activation of Plexin-B1, promoting metastatic cell characteristics in human breast cancer cells and reducing prognosis in human patients.
The new drug Vemurafenib doubles the median survival time of metastatic melanoma patients with a specific genetic mutation, from 6 months to 15.9 months. In responding patients, the drug stops cancer progression for an additional 6.7 months.
Scientists at UCSF found simultaneous targeting of two molecules can effectively shrink tumors, block invasion, and stop metastasis in mice. The approach may improve combination treatments, including drugs like Avastin, for various cancer types.
Dual inhibition of VEGF and c-MET signaling inhibits tumor invasion and metastasis in a laboratory model of pancreatic neuroendocrine cancer. Inhibition of VEGF alone increases c-MET expression, leading to increased invasiveness and metastasis.
Researchers at UCSF have discovered a new class of drugs that target the mTOR protein, which is hyperactive in many forms of cancer. The new drugs block mTOR more completely than previous ones, effectively hobbles cancer cells and prevents metastasis.
Researchers at Weill Cornell Medical College found that a single protein, versican, is key to reversing the process of cancer metastasis in breast cancer. When versican was stopped from functioning, breast cancer could not seed itself into the lungs and form secondary tumors.
A study published in American Journal of Pathology reveals that trefoil factor 3 (TFF3) protein, which protects the epithelial surface in normal breast tissue, also promotes tumor invasion and metastasis in breast cancer. Higher TFF3 expression is associated with a more aggressive phenotype.
Researchers discovered that nonsteroidal anti-inflammatory drugs (NSAIDS) inhibit tumor metastasis by reducing lymphatic vessel dilation and prostaglandin pathways. This mechanism provides a potential target for cancer treatment.
Inflammatory breast cancer cells use the anti-inflammatory response of white blood cells to increase fibronectin expression, a molecule involved in wound healing and cell migration. Monocyte-conditioned media stimulate this process through the IL-8 signaling pathway, allowing cancer cells to branch and invade, leading to metastasis.
The American Society for Radiation Oncology (ASTRO) has developed a clinical practice guideline for the radiotherapeutic and surgical management of newly diagnosed brain metastases. The guideline provides evidence-based recommendations for choosing treatment modalities based on tumor factors and prognosis.
Researchers at Ohio State University have discovered a pattern of microRNAs that distinguishes early-stage breast tumors from deadly, invasive cancer. The findings suggest a potential biomarker for identifying high-risk DCIS tumors that may become invasive.
Research from the 2012 Genitourinary Cancers Symposium highlights promising new therapies for prostate cancer, including vigorous exercise and targeted drugs that improve survival rates. The studies also compare existing treatments, such as radiation therapy and hormone therapy, to determine their effectiveness.
Researchers at Scripps Research Institute found that a cell surface protein called CDCP1 protects tumor cells from apoptosis and promotes metastasis. The team identified plasmin as the key enzyme responsible for cleaving CDCP1, which triggers a signaling cascade blocking apoptosis and enabling cancer cells to colonize distant organs.
A new molecular test can predict the likelihood of death from early-stage lung cancer with greater accuracy than traditional methods. The test, which measures gene activity in cancerous tissue, has been shown to improve prognosis and guide treatment decisions for patients with non-squamous non-small cell lung cancer.
Researchers at Wayne State University are investigating the role of c-kit in bone metastasis of prostate cancer. They aim to understand how factors from the bone stimulate the production of c-kit and its ligand in prostate cancer cells, facilitating their growth and survival.
Researchers at the University of Pennsylvania School of Medicine have discovered that pancreatic cancer cells in an animal model begin to spread before clinically obvious tumor tissue is detected. Inflammation plays a crucial role in enhancing cancer progression, leading to the entry of cancer cells into the bloodstream. The study used...
A new study finds that pericytes, a group of cells in the tumor microenvironment, play a crucial role in preventing cancer progression and metastasis. Researchers discovered that inhibiting these cells can inadvertently make tumors more aggressive and likely to spread.
Researchers at the University of Granada have identified genetic and phenotypic changes that lead to tumor progression and metastasis. Circulating tumor cells can adapt to hostile environments and resist treatment, causing metastasis.
Researchers have developed targeted, fluorescent molecular imaging probes that can non-invasively detect breast cancer lymph node metastases, improving breast cancer staging and prognosis. CAIX and CAXII cell surface markers are highly expressed in breast cancer lymph node metastases.
Research finds that ISG15 pathway disrupts cytoskeletal architecture in breast cancer cells, promoting cell migration and invasion. The study suggests that targeting the ISG15 pathway could provide a therapeutic advantage for patients with metastatic tumors.
Scientists at Thomas Jefferson University's Center for Translational Medicine have found that reducing N-cadherin levels in pancreatic cancer cells can slow down their mobility and prolong survival in mice by 25 percent. This discovery could lead to new targeted therapies for pancreatic cancer.
Researchers found that increasing EET levels promotes tumor growth and metastasis, even in cancers that rarely spread. Blocking EETs, however, could reduce tumor growth and metastasis, suggesting a potential new avenue for cancer treatment.
A team of researchers found that raising levels of epoxyeicosatrienoic acids (EETs) in mice stimulated primary tumor growth and metastasis, suggesting potential risks for humans. EET antagonists may provide a new approach to preventing and treating cancer-related metastasis.
Researchers found that EET-enhancing drugs promote tumor growth and metastasis in mice, raising concerns about their use in humans. The findings suggest that these drugs could also worsen cardiovascular diseases.
Researchers found that blocking EETs production can eliminate blood vessels that feed cancer tumors, promoting metastasis. Increasing EET levels may help patients with vascular conditions, but excessive levels promote tumor growth and metastasis.
Combining bevacizumab with standard chemoradiation therapy prolongs survival and delays disease progression in patients with advanced nasopharyngeal carcinoma. The study results show over 90% of patients surviving 2 years without distant metastases.
Researchers at Moffitt Cancer Center have identified a chemical disrupter of the Rb-Raf-1 interaction, which may be vulnerable to targeting to prevent cancer cell proliferation and tumor growth. The study found that this disruption can limit metastasis in test mice, suggesting a potential new approach for combating metastatic disease.
Researchers found that tumors with high microRNA-200c levels are more likely to spread and those with lower levels may benefit from focused local treatment. This discovery could help identify patients who can benefit from aggressive, targeted radiation therapy and move them away from whole-body treatments.
Women with newly diagnosed inflammatory breast cancer who have stray tumor cells in their blood should receive aggressive treatment, regardless of imaging results. Researchers found no correlation between circulating tumor cells and survival rates in these patients.
A recent study found that clodronate had a low incidence of adverse events and toxicity among patients with breast cancer. The treatment modestly reduced the incidence of distant metastases in postmenopausal women, with a relative reduction of 9% compared to placebo.
Scientists isolated a protein called periostin that plays a major role in metastasis development. Blocking this protein can prevent the formation of secondary cancers, offering a promising therapeutic option for late-stage cancers.
Researchers have discovered a drug that can alter the DNA of uveal melanoma cells, rendering them less aggressive. The treatment, known as histone deacetylase inhibitors, may slow or prevent tumor growth in patients with metastatic eye cancer.
A team of UNC scientists has identified P-Rex1 protein as a crucial factor in the movement of melanoblasts, leading to melanoma development. The study found that mice lacking this protein are resistant to melanoma metastasis, suggesting P-Rex1 plays an important role in cancer spread.
A new study from the University of Hawaii Cancer Center found that PEA-15 protein enhances tumor formation in kidney cells carrying a mutation in the cancer-promoting gene H-Ras. The discovery suggests caution in pursuing PEA-15 as an anti-cancer therapeutic, highlighting its dual role in cancer growth and suppression.
A clinical trial found that denosumab treatment increases bone-metastasis-free survival by an average of four months in men with prostate cancer. The drug targets the bone microenvironment to prevent tumor spread.
A study published in The Lancet shows denosumab can delay time to bone metastasis in men with castration-resistant prostate cancer. Denosumab significantly increases bone-metastasis-free survival by over four months compared to placebo, with improved outcomes also seen in delayed first bone metastasis.
A study by MIT cancer biologists reveals that platelets release chemical signals inducing tumor cells to become more invasive and form new tumors. The findings suggest that direct physical contact between platelets and tumor cells is necessary for metastasis, highlighting potential targets for drug development.
Scientists discovered that variant forms of tyrosine can slow tumor growth and prevent metastasis. This finding could lead to a simple and safe type of therapy to manage malignant disease.
Researchers found that elevated TGF beta levels lead to fascin overexpression, promoting tumor metastasis. High fascin expression is associated with poor prognosis.
The National Cancer Institute has awarded Albert Einstein College of Medicine two grants totaling $8 million to study the microenvironments that drive the spread of cancer. The research aims to understand the complex process of metastasis, which is responsible for most cancer-related deaths.
A University of Rochester analysis found that older men are more likely to die from prostate cancer due to late-stage diagnosis. The study's lead author notes that overall health plays a significant role in life expectancy following a cancer diagnosis.
Scientists propose 'Lance Armstrong effect' to overcome resistance in pancreatic and other cancers, with promising results in testicular cancer patients who beat metastatic disease despite low survival rates elsewhere. Researchers explore nanoparticle therapies to target tumors with high temperatures.
Researchers at Medical College of Wisconsin show that CXCL12 protein inhibits metastasis in colon and melanoma cancers. The protein, naturally expressed in bone marrow and other organs prone to cancer metastasis, effectively blocks tumor growth and improves survival time.
Studies reveal the role of Sirt1 in improving insulin sensitivity through caloric restriction. Researchers also identify a potential treatment approach for KRAS mutant colorectal cancers by combining receptor tyrosine kinase inhibitors with MEK inhibitors. Additionally, new insights into the cellular defects of Huntington disease are p...
Researchers found widespread disagreement among scientists studying cancer metastasis, with no two scenarios identical. The study suggests making assumptions explicit can improve biomedical modeling and create new opportunities for understanding alternative theories.
A U-M study has identified the p38-gamma molecule as a key regulator of aggressive breast cancer cell movement. By understanding how this molecule influences cell motion, researchers hope to develop targeted therapies that can improve treatment outcomes.
A new study uses the Tilman model of competition between invasive species to understand how prostate cells invade bone marrow and take over the microenvironment. The research reveals that cancer cells follow a similar path to ecological invasions, highlighting the potential for ecological modeling to understand metastasis.
A new trial shows that a single dose of the drug ibandronate is as effective in controlling pain from prostate cancer bone metastases as a single dose of radiotherapy. The study found no long-term difference in pain relief between the two treatments.
Researchers have developed a new bone-targeting drug that can delay the onset of metastases in hormone-resistant prostate cancer patients. The study showed that denosumab prolonged bone metastasis-free survival significantly compared to placebo, improving patient quality of life.
A Phase III trial of Radium-223 Chloride has shown improved survival rates among patients with bone metastases from advanced prostate cancer. The study found that patients taking radium-223 had a 30% lower rate of death compared to those receiving placebo.
A new treatment, percutaneous hepatic perfusion (PHP), has been shown to significantly extend the time patients with liver-dominant metastatic melanoma can live without disease progression. On average, PHP patients survived for 8.1 months, compared to 1.6 months in the control group.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a gene-based imaging system that can detect castration-resistant prostate cancer earlier than conventional methods. The system uses specific genes and reporter genes to accurately identify the spread of the disease, giving oncologists more time to treat it and pot...
Researchers found that soy peptide lunasin binds to receptors in highly metastatic colon cancer cells, preventing them from attaching to the liver. Combining lunasin with chemotherapy drug oxaliplatin resulted in a sixfold reduction in new tumor sites.
Researchers have identified a protein that plays a critical role in heart development and may also be a therapeutic target for halting colon cancer metastasis. BVES expression was found to be low in all stages of colon cancer and decreased levels were observed in many other types of epithelial cancers.
Researchers found that breast tumor cells can evade NK cell antitumor activity by promoting self-tolerance. The study suggests that restoring NK cell function could benefit individuals with breast cancer.
Researchers have identified new genetic markers for patients at high risk for bone metastasis, which may provide additional targets for preventing and treating the disease. A novel vaccine for HER2+ breast cancer is also being developed to address a particularly aggressive form of the disease.
A study found no association between occult metastases in lymph nodes and overall survival among women with early-stage breast cancer. Researchers detected micro-metastases using immunohistochemical staining but did not find significant impact on death or recurrence rates.
A high-throughput screen identified several compounds that inhibit invadopodia formation, a key step in cancer cell invasion. In contrast, another compound, paclitaxel, was found to promote invadopodia formation and cancer cell invasion.
A study published in Clinical Cancer Research found that trastuzumab, chemotherapy, and surgery significantly improved overall survival in HER2-positive breast and brain cancer patients. Treatment with these therapies led to improved survival rates of up to 20 months for those with central nervous system metastases.
The European Commission has approved YERVOY (ipilimumab) for treating adult patients with previously-treated advanced melanoma. The treatment showed long-term survival rates of 46% and 24% at 1 and 2 years, respectively. YERVOY works by stimulating the immune system to recognize and destroy cancer cells.